

**Additional Table 1: Cardiovascular indications for O<sub>3</sub> therapy**

Study	Pathology	Concentration and route of O <sub>3</sub> administration	Type of study	Measured parameter(s)	Results	Side effect(s)	Mechanism of action
Martínez-Sánchez et al. <sup>14</sup>	Coronary artery disease	57 patients with massive cerebral infarction	Ungrouped; cocktail therapy: nimodipine (10 mg) intravenously, once per day, for 10 consecutive days	Prothrombin time Oxidative stress levels	Significantly improved ( $P < 0.001$ ) Increased antioxidant activity	None None	Upregulation of adenosine A <sub>2</sub> receptor Increased SOD and catalase enzyme activity
Hernandez et al. <sup>40</sup>	Previous myocardial infarction (3 months to 1 year)	200 mL of blood subjected to O <sub>3</sub> -AHT, for a final concentration of 50 mg/L; treatment was given 5 days a week for up to 15 sessions	Pretest-posttest design ( $n = 22$ )	Serum lipid pattern Activity of antioxidant defense system	Cholesterol and low-density lipoprotein were significantly reduced with no changes in high-density lipoprotein and triglycerides Biologically significant increases on erythrocyte GPx and glucose-6-phosphate dehydrogenase	Not reported Not reported	Initiating radical formation which increasing lipid peroxidation O <sub>3</sub> -AHT stimulates ROS scavenger enzymes

Note: O<sub>3</sub>: Ozone; O<sub>2</sub>: oxygen; O<sub>3</sub>-AHT: O<sub>3</sub> autohemotransfusion; GPx: glutathione peroxidase; SOD: superoxide dismutase; ROS: reactive oxidative species.